Indivi, a Basel-based Tech Bio company specializing in precision medicine for neuroscience, announced the successful closing of a CHF 15 million investment round led by Ava Investors. The new funding will accelerate the validation and deployment of Indivi’s precision medicine tools in early-phase neuroscience drug development, with a specific focus on Alzheimer’s disease.
The company plans to launch a proof-of-concept trial in 2026 to identify functional and electrophysiological biomarkers that can demonstrate superior pharmacodynamic responses in Alzheimer’s disease modification through β-amyloid-depleting therapies. The anticipated results could lead to the establishment of novel, more sensitive biomarkers, thereby improving the ability to detect early treatment efficacy signals in Alzheimer’s disease clinical trials.
The investment comes at a critical time for the neuroscience sector, which continues to face challenges in developing effective therapies for neurodegenerative diseases. Indivi aims to improve the probability of clinical success by integrating accessible deep phenotyping technologies into drug development.
Indivi’s platform focuses on capturing early treatment benefits in complex neurological diseases using its proprietary software for deep phenotyping. The company’s approach combines functional and biological measurements—such as electrophysiology and sensor-derived assessments—to deliver earlier and more definitive Proof-of-Biology and Proof-of-Concept signals in neuroscience research.
Headquartered in Basel, Indivi develops functional biomarkers for a range of neurological and neuromuscular conditions, including multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and related dementias, as well as muscular dystrophies. Through its partnership with Clouds of Care, Indivi has developed a unified R&D framework for multimodal deep phenotyping, aiming to accelerate early-stage neuroscience drug development.
By enhancing the signal-to-noise ratio of early-stage clinical endpoints, Indivi’s integrated approach de-risks early clinical development, increases the likelihood of regulatory success, and improves the risk-adjusted net present value for biopharmaceutical partners seeking to advance therapies for neurodegenerative diseases.
KEY QUOTES:
“The field of neurodegeneration remains one of the toughest challenges in medicine. We are thrilled to bolster our efforts to augment the success rate of promising assets to reach the Proof-of-Concept stage, where conventional endpoints lack the sensitivity needed to detect early treatment effects.”
Shibeshih Belachew, Chief Medical Officer of Indivi
“Our mission is to make measurable what is not so, by capturing early treatment benefits on complex neurological disease traits through accessible deep phenotyping software technologies.”
Guilhem Dupont, Chief Executive Officer of Indivi
